These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 8092840)
1. Interaction of oxyimino beta-lactams with a class C beta-lactamase and a mutant with a spectrum extended to beta-lactams. Nukaga M; Tsukamoto K; Yamaguchi H; Sawai T Antimicrob Agents Chemother; 1994 Jun; 38(6):1374-7. PubMed ID: 8092840 [TBL] [Abstract][Full Text] [Related]
2. The effect of amino acid substitution at position 219 of Citrobacter freundii cephalosporinase on extension of its substrate spectrum. Tsukamoto K; Ohno R; Nukaga M; Sawai T Eur J Biochem; 1992 Aug; 207(3):1123-7. PubMed ID: 1499556 [TBL] [Abstract][Full Text] [Related]
3. Extension of the substrate spectrum by an amino acid substitution at residue 219 in the Citrobacter freundii cephalosporinase. Tsukamoto K; Ohno R; Sawai T J Bacteriol; 1990 Aug; 172(8):4348-51. PubMed ID: 2115867 [TBL] [Abstract][Full Text] [Related]
4. Effect of an amino acid insertion into the omega loop region of a class C beta-lactamase on its substrate specificity. Nukaga M; Taniguchi K; Washio Y; Sawai T Biochemistry; 1998 Jul; 37(29):10461-8. PubMed ID: 9671516 [TBL] [Abstract][Full Text] [Related]
5. Characterization of an extended-spectrum class C beta-lactamase of Citrobacter freundii. Haruta S; Nukaga M; Sawai T Microbiol Immunol; 2001; 45(4):277-83. PubMed ID: 11386417 [TBL] [Abstract][Full Text] [Related]
6. Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases. Sakurai Y; Yoshida Y; Saitoh K; Nemoto M; Yamaguchi A; Sawai T J Antibiot (Tokyo); 1990 Apr; 43(4):403-10. PubMed ID: 2112533 [TBL] [Abstract][Full Text] [Related]
7. Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis. Kimura S; Ishiguro M; Ishii Y; Alba J; Yamaguchi K Antimicrob Agents Chemother; 2004 May; 48(5):1454-60. PubMed ID: 15105092 [TBL] [Abstract][Full Text] [Related]
8. Resistance to oxyimino beta-lactams due to a mutation of chromosomal beta-lactamase in Citrobacter freundii. Haruta S; Nukaga M; Taniguchi K; Sawai T Microbiol Immunol; 1998; 42(3):165-9. PubMed ID: 9570281 [TBL] [Abstract][Full Text] [Related]
9. Substitution of aspartic acid-217 of Citrobacter freundii cephalosporinase and properties of the mutant enzymes. Tsukamoto K; Kikura R; Ohno R; Sawai T FEBS Lett; 1990 May; 264(2):211-4. PubMed ID: 1972682 [TBL] [Abstract][Full Text] [Related]
10. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases. Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of beta-lactamase inhibition: differences between sulbactam and other inhibitors. Sawai T; Yamaguchi A Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):121S-129S. PubMed ID: 2591172 [TBL] [Abstract][Full Text] [Related]
12. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria. Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329 [TBL] [Abstract][Full Text] [Related]
13. Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 beta-lactamase with altered substrate specificity for aztreonam and ceftazidime. Cantu C; Huang W; Palzkill T J Biol Chem; 1996 Sep; 271(37):22538-45. PubMed ID: 8798421 [TBL] [Abstract][Full Text] [Related]
14. Role of lysine-67 in the active site of class C beta-lactamase from Citrobacter freundii GN346. Tsukamoto K; Tachibana K; Yamazaki N; Ishii Y; Ujiie K; Nishida N; Sawai T Eur J Biochem; 1990 Feb; 188(1):15-22. PubMed ID: 1969344 [TBL] [Abstract][Full Text] [Related]
15. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Quinn JP; Miyashiro D; Sahm D; Flamm R; Bush K Antimicrob Agents Chemother; 1989 Sep; 33(9):1451-6. PubMed ID: 2684007 [TBL] [Abstract][Full Text] [Related]
16. Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams. Vakulenko SB; Tóth M; Taibi P; Mobashery S; Lerner SA Antimicrob Agents Chemother; 1995 Aug; 39(8):1878-80. PubMed ID: 7486939 [TBL] [Abstract][Full Text] [Related]
17. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases. Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290 [TBL] [Abstract][Full Text] [Related]
18. Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N Ourghanlian C; Soroka D; Arthur M Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069651 [TBL] [Abstract][Full Text] [Related]
19. Novel carbapenem derivative SF2103A: studies on the mode of beta-lactamase inactivation. Yamaguchi A; Hirata T; Sawai T Antimicrob Agents Chemother; 1984 Mar; 25(3):348-53. PubMed ID: 6372682 [TBL] [Abstract][Full Text] [Related]
20. The in-vitro activity and beta-lactamase stability of carumonam. Neu HC; Chin NX; Labthavikul P J Antimicrob Chemother; 1986 Jul; 18(1):35-44. PubMed ID: 3531143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]